Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Europe Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2025-2033
Report Format: PDF+Excel | Report ID: SR112024A1023
Buy Now
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Europe Biosimilars Market – Introduction
4.1 Overview
4.2 WHO and EMA Terminology on Biosimilars
4.3 Biosimilars and Generics
4.4 Biosimilars and Branded Biological Products
5 Europe Biosimilars Market
5.1 Market Overview
5.2 Historical and Current Market Trends
5.3 Impact of COVID-19
5.4 Market Breakup by Country
5.5 Market Breakup by Molecule
5.6 Market Breakup by Indication
5.7 Market Breakup by Manufacturing Type
5.8 Patent Landscape
5.9 Market Forecast
6 Market Breakup by Country
6.1 Italy
6.1.1 Market Performance
6.1.2 Key Players and Biosimilars
6.1.3 Market Forecast
6.2 Germany
6.2.1 Market Performance
6.2.2 Key Players and Biosimilars
6.2.3 Market Forecast
6.3 France
6.3.1 Market Performance
6.3.2 Key Players and Biosimilars
6.3.3 Market Forecast
6.4 United Kingdom
6.4.1 Market Performance
6.4.2 Key Players and Biosimilars
6.4.3 Market Forecast
6.5 Spain
6.5.1 Market Performance
6.5.2 Key Players and Biosimilars
6.5.3 Market Forecast
6.6 Rest of Europe
6.6.1 Market Performance
6.6.2 Market Forecast
7 Market Breakup by Molecule
7.1 Infliximab
7.2 Insulin Glargine
7.3 Epoetin Alfa
7.4 Etanercept
7.5 Filgrastim
7.6 Somatropin
7.7 Rituximab
7.8 Follitropin Alfa
7.9 Adalimumab
8 Market Breakup by Manufacturing Type
8.1 In-house Manufacturing
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Contract Manufacturing
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Indication
9.1 Auto-Immune Diseases
9.2 Blood Disorder
9.3 Diabetes
9.4 Oncology
9.5 Growth Deficiency
9.6 Female Infertility
10 European Biosimilar Market: SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 European Biosimilar Market: Value Chain Analysis
11.1 Characterizing the Existing Innovator Drug
11.2 Research and Development
11.2.1 Characterization of Biosimilars
11.2.2 Developing a Unique Cell Line
11.3 Product Development
11.3.1 Pre-Testing
11.3.2 Intermediary Clinical Testing (PK/PD)
11.3.3 Confirmatory Clinical Phase-III
11.4 Final Product Formulation
11.5 Marketing and Distribution
12 Porter’s Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
13.1 Key Price Indicators
13.2 Price Trends
14 Requirements for Setting Up a Generic Drug Manufacturing Plant
14.1 Manufacturing Process
14.2 Raw Material Requirements
14.3 Raw Material Pictures
14.4 Land and Construction Requirements
14.5 Machinery and Infrastructure Requirements
14.6 Machinery Pictures
14.7 Plant Layout
14.8 Packaging Requirements
14.9 Utility Requirements
14.10 Manpower Requirements
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Novartis
15.3.2 Pfizer
15.3.3 Teva
15.3.4 Celltrion
15.3.5 Merck Sharp & Dohme
15.3.6 Samsung Bioepis
15.3.7 Eli Lilly
15.3.8 Accord Healthcare Ltd.
15.3.9 Amgen
15.3.10 Boehringer Ingelheim
15.3.11 Hexal Ag
15.3.12 Apotex
15.3.13 Stada Arzneimittel Ag
15.3.14 Ratiopharm
15.3.15 Mylan
List of Figures
Figure 1: Europe: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 2: Europe: Biosimilar Market: Breakup by Molecule (in %), 2024
Figure 3: Europe: Biosimilar Market: Breakup by Manufacturing Type (in %), 2024
Figure 4: Europe: Biosimilar Market: Breakup by Indication (in %), 2024
Figure 5: Europe: Biosimilar Market: Breakup by Country (in %), 2024
Figure 6: Europe: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 7: Italy: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 8: Italy: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 9: Germany: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 10: Germany: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: France: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 12: France: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: United Kingdom: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 14: United Kingdom: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Spain: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 16: Spain: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Rest of Europe: Biosimilar Market: Sales Value (in Million USD), 2019-2024
Figure 18: Rest of Europe: Biosimilar Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Europe: Rituximab Biosimilar Market: Sales Value (in Million USD), 2017
Figure 20: Europe: Infliximab Biosimilar Market: Sales Value (in Million USD), 2015 - 2017
Figure 21: Europe: Insulin Glargine Biosimilar Market: Sales Value (in Million USD), 2016 & 2017
Figure 22: Europe: Epoetin Alfa Biosimilar Market: Sales Value (in Million USD), 2014 - 2017
Figure 23: Europe: Filgrastim Biosimilar Market: Sales Value (in Million USD), 2014 - 2017
Figure 24: Europe: Somatropin Biosimilar Market: Sales Value (in Million USD), 2014 - 2017
Figure 25: Europe: Etanercept Biosimilar Market: Sales Value (in Million USD), 2016 & 2017
Figure 26: Europe: Follitropin Alfa Biosimilar Market: Sales Value (in Million USD), 2015 - 2017
Figure 27: Europe: Adalimumab Biosimilar Market: Sales Value (in Million USD), 2018
Figure 28: Europe: Biosimilar Market (In-House Manufacturing): Sales Value (in Million USD), 2019 & 2024
Figure 29: Europe: Biosimilar Market Forecast (In-House Manufacturing): Sales Value (in Million USD), 2025-2033
Figure 30: Europe: Biosimilar Market (Contract Manufacturing): Sales Value (in Million USD), 2019 & 2024
Figure 31: Europe: Biosimilar Market Forecast (Contract Manufacturing): Sales Value (in Million USD), 2025-2033
Figure 32: Europe: Biosimilar Market (Autoimmune Diseases): Sales Value (in Million USD), 2019 & 2024
Figure 33: Europe: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million USD), 2025-2033
Figure 34: Europe: Biosimilar Market (Blood Disorders): Sales Value (in Million USD), 2019 & 2024
Figure 35: Europe: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million USD), 2025-2033
Figure 36: Europe: Biosimilar Market (Diabetes): Sales Value (in Million USD), 2019 & 2024
Figure 37: Europe: Biosimilar Market Forecast (Diabetes): Sales Value (in Million USD), 2025-2033
Figure 38: Europe: Biosimilar Market (Oncology): Sales Value (in Million USD), 2019 & 2024
Figure 39: Europe: Biosimilar Market Forecast (Oncology): Sales Value (in Million USD), 2025-2033
Figure 40: Europe: Biosimilar Market (Growth Deficiency): Sales Value (in Million USD), 2019 & 2024
Figure 41: Europe: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million USD), 2025-2033
Figure 42: Europe: Biosimilar Market (Female Infertility): Sales Value (in Million USD), 2019 & 2024
Figure 43: Europe: Biosimilar Market Forecast (Female Infertility): Sales Value (in Million USD), 2025-2033
Figure 44: Europe: Biosimilar Industry: SWOT Analysis
Figure 45: Europe: Biosimilar Industry: Value Chain Analysis
Figure 46: Europe: Biosimilar Industry: Porter’s Five Forces Analysis
Figure 47: Biosimilar Manufacturing: Detailed Process Flow
List of Tables
Table 1: Europe: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million USD)
Table 2: Biosimilar vs. Innovators Drug Development
Table 3: Biosimilar vs. Biologics Manufacturing
Table 4: Europe: Biosimilar Market: Key Industry Highlights, 2024 and 2033
Table 5: Europe: Biosimilar Market: Patent Landscape
Table 6: Europe: Biosimilar Market: Price Comparison Between Biosimilar and Originator Drugs
Table 7: Europe: Biosimilar Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 8: Europe: Biosimilar Market: Key Players and Biosimilars
Table 9: Italy: Biosimilar Market: Key Players and Biosimilars
Table 10: Germany: Biosimilar Market: Key Players and Biosimilars
Table 11: France: Biosimilar Market: Key Players and Biosimilars
Table 12: United Kingdom: Biosimilar Market: Key Players and Biosimilars
Table 13: Spain: Biosimilar Market: Key Players and Biosimilars
Table 14: Europe: Rituximab: Brand & Biosimilar Market Overview
Table 15: Europe: Infliximab: Brand & Biosimilar Market Overview
Table 16: Europe: Insulin Glargine: Brand & Biosimilar Market Overview
Table 17: Europe: Epoetin Alfa: Brand & Biosimilar Market Overview
Table 18: Europe: Filgrastim: Brand & Biosimilar Market Overview
Table 19: Europe: Somatropin: Brand & Biosimilar Market Overview
Table 20: Europe: Etanercept: Brand & Biosimilar Market Overview
Table 21: Europe: Follitropin Alfa: Brand & Biosimilar Market Overview
Table 22: Europe: Biosimilar Market Forecast: Breakup by Manufacturing Type (in Million USD), 2025-2033
Table 23: Europe: Biosimilar Market Forecast: Breakup by Indication (in Million USD), 2025-2033
Table 24: Biosimilar Manufacturing Plant: Raw Material Requirements
Table 25: Biosimilar Manufacturing Plant: Land and Construction Requirements
Table 26: Biosimilar Manufacturing Plant: Machinery Requirements
Table 27: Biosimilar Manufacturing Plant: Manpower Requirements
Table 28: Europe: Biosimilar Market: Competitive Structure
Table 29: Europe: Biosimilar Market: Key Players
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More
IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.
Read More
I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested
Read More
Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.
Read More
The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.
Read More
I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you
Read More
The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.
Read More
One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.
Read More
We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.
Read More
The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.
Read More
The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.
Read More
The report is excellent and has good amount of data and our team is extremely happy with the information provided.
Read More
Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.
Read More